Comparative Pharmacology
Head-to-head clinical analysis: BETHKIS versus TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETHKIS versus TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
BETHKIS vs TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tobramycin, an aminoglycoside antibiotic, binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis, leading to bacterial cell death.
Tobramycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis in susceptible bacteria.
4 IU/kg (1 mg/kg) intramuscularly or subcutaneously once weekly for 4 weeks, then a maintenance dose of 2 IU/kg (0.5 mg/kg) once weekly.
3-5 mg/kg/day IV divided every 8 hours or 5-7 mg/kg IV once daily for adults with normal renal function.
None Documented
None Documented
Terminal elimination half-life 2-3 hours in patients with normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min).
2-3 hours in patients with normal renal function; prolonged to 24-60 hours in anuria. Half-life is directly correlated with creatinine clearance.
Primarily renal excretion of unchanged drug via glomerular filtration; ~90% of absorbed dose excreted in urine within 24 hours; biliary/fecal elimination <5%.
Primarily renal (glomerular filtration) with >90% excreted unchanged in urine within 24 hours; minimal biliary/fecal (<1%).
Category C
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic